Phenominer Database Results (16 results)

 
 
How to display a graph
Strain Phenotype Conditions Study Experiment Name Sex Age # of Animals Value Units SEM SD Method Method Site Method Duration Post Insult Time Value Method Notes Clinical Measurement Notes Record ID Study ID
SHRSP/A3N systolic blood pressure controlled sodium chloride content drinking water (1 %) (for 126 days) and controlled fat content diet (24.5 %) (for 126 days) and controlled carvedilol content diet (2400 ppm) (for 126 days) Barone FC, etal., Pharmacology. 2007;80(2-3):166-76. doi: 10.1159/000103384. Epub 2007 Jun 4. arterial blood pressure trait male 203 days-224 days 10 260.0 mmHg 6.0 18.97 tail cuff plethysmography tail 0.0 0 107095 3075
SHRSP/A3N interstitial nephritis foci count controlled sodium content drinking water (1 %) (for 126 days) and controlled fat content diet (24.5 %) (for 126 days) and controlled carvedilol content diet (2400 ppm) (for 126 days) Wong VY, etal., Br J Pharmacol. 2001 Nov;134(5):977-84. doi: 10.1038/sj.bjp.0704329. kidney integrity trait male 210 days-224 days 0 2.4 /section 0.8 ex vivo light microscopy with histochemistry 0.0 0 foci of interstitial nephritis 107490 3088
SHRSP/A3N renal fibrosis foci count controlled sodium content drinking water (1 %) (for 126 days) and controlled fat content diet (24.5 %) (for 126 days) and controlled carvedilol content diet (2400 ppm) (for 126 days) Wong VY, etal., Br J Pharmacol. 2001 Nov;134(5):977-84. doi: 10.1038/sj.bjp.0704329. kidney integrity trait male 210 days-224 days 0 15.0 /section 2.0 ex vivo light microscopy with histochemistry 0.0 0 foci of renal fibrosis 107498 3088
SHRSP/A3N heart rate controlled sodium chloride content drinking water (1 %) (for 126 days) and controlled fat content diet (24.5 %) (for 126 days) and controlled carvedilol content diet (2400 ppm) (for 126 days) Barone FC, etal., Pharmacology. 2007;80(2-3):166-76. doi: 10.1159/000103384. Epub 2007 Jun 4. heart pumping trait male 203 days-224 days 10 280.0 beats/min 4.0 12.65 tail cuff plethysmography 0.0 0 high salt high fat diet +carvedilol 107116 3075
SHRSP/A3N body weight controlled sodium content drinking water (1 %) (for 126 days) and controlled fat content diet (24.5 %) (for 126 days) and controlled carvedilol content diet (2400 ppm) (for 126 days) Barone FC, etal., Pharmacology. 2007;80(2-3):166-76. doi: 10.1159/000103384. Epub 2007 Jun 4. body mass male 203 days-224 days 10 367.0 g 10.0 31.62 body weighing method 0.0 0 high salt high fat diet +carvedilol 107103 3075
SHRSP/A3N end-diastolic volume controlled sodium content drinking water (1 %) (between 112 and 126 days) and controlled fat content diet (24.5 %) (between 112 and 126 days) and controlled carvedilol content diet (2400 ppm) (between 112 and 126 days) Barone FC, etal., Pharmacology. 2007;80(2-3):166-76. doi: 10.1159/000103384. Epub 2007 Jun 4. cardiac output trait male 189 days-210 days 0 0.96 ml 0.02 transthoracic echocardiography 0.0 0 high salt high fat diet +carvedilol 107121 3075
SHRSP/A3N kidney tubule regeneration foci count controlled sodium content drinking water (1 %) (for 126 days) and controlled fat content diet (24.5 %) (for 126 days) and controlled carvedilol content diet (2400 ppm) (for 126 days) Wong VY, etal., Br J Pharmacol. 2001 Nov;134(5):977-84. doi: 10.1038/sj.bjp.0704329. kidney integrity trait male 210 days-224 days 0 1.9 /section 1.3 ex vivo light microscopy with histochemistry 0.0 0 foci of tubular regeneration 107486 3088
SHRSP/A3N end-systolic volume controlled sodium content drinking water (1 %) (between 112 and 126 days) and controlled fat content diet (24.5 %) (between 112 and 126 days) and controlled carvedilol content diet (2400 ppm) (between 112 and 126 days) Barone FC, etal., Pharmacology. 2007;80(2-3):166-76. doi: 10.1159/000103384. Epub 2007 Jun 4. cardiac output trait male 189 days-210 days 0 0.28 ml 0.03 transthoracic echocardiography 0.0 0 high salt high fat diet +carvedilol 107125 3075
SHRSP/A3N end-diastolic volume controlled sodium chloride content drinking water (1 %) (for 126 days) and controlled fat content diet (24.5 %) (for 126 days) then controlled carvedilol content diet (2400 ppm) (for 42 days) Barone FC, etal., Pharmacology. 2007;80(2-3):166-76. doi: 10.1159/000103384. Epub 2007 Jun 4. cardiac output trait male 203 days-224 days 8 1.08 ml 0.07 0.2 transthoracic echocardiography 0.0 0 hsfd +carvedilol reversal 107134 3075
SHRSP/A3N kidney glomerular lesion count controlled sodium content drinking water (1 %) (for 126 days) and controlled fat content diet (24.5 %) (for 126 days) and controlled carvedilol content diet (2400 ppm) (for 126 days) Wong VY, etal., Br J Pharmacol. 2001 Nov;134(5):977-84. doi: 10.1038/sj.bjp.0704329. kidney glomerulus integrity trait male 210 days-224 days 0 4.0 /section 2.0 ex vivo light microscopy with histochemistry 0.0 0 107478 3088
SHRSP/A3N end-systolic volume controlled sodium chloride content drinking water (1 %) (for 126 days) and controlled fat content diet (24.5 %) (for 126 days) then controlled carvedilol content diet (2400 ppm) (for 42 days) Barone FC, etal., Pharmacology. 2007;80(2-3):166-76. doi: 10.1159/000103384. Epub 2007 Jun 4. cardiac output trait male 203 days-224 days 8 0.36 ml 0.07 0.2 transthoracic echocardiography 0.0 0 hsfd +carvedilol reversal 107136 3075
SHRSP/A3N heart rate controlled sodium chloride content drinking water (1 %) (for 126 days) and controlled fat content diet (24.5 %) (for 126 days) then controlled carvedilol content diet (2400 ppm) (for 42 days) Barone FC, etal., Pharmacology. 2007;80(2-3):166-76. doi: 10.1159/000103384. Epub 2007 Jun 4. heart pumping trait male 203 days-224 days 8 236.0 beats/min 8.0 22.63 transthoracic echocardiography 0.0 0 hsfd +carvedilol reversal 107138 3075
SHRSP/A3N heart rate controlled sodium content drinking water (1 %) (between 112 and 126 days) and controlled fat content diet (24.5 %) (between 112 and 126 days) and controlled carvedilol content diet (2400 ppm) (between 112 and 126 days) Barone FC, etal., Pharmacology. 2007;80(2-3):166-76. doi: 10.1159/000103384. Epub 2007 Jun 4. heart pumping trait male 189 days-210 days 0 254.0 beats/min 10.0 transthoracic echocardiography 0.0 0 high salt high fat diet +carvedilol 107129 3075
SHRSP/A3N urine total protein excretion rate controlled sodium content drinking water (1 %) (for 126 days) and controlled fat content diet (24.5 %) (for 126 days) and controlled carvedilol content diet (2400 ppm) (for 126 days) Wong VY, etal., Br J Pharmacol. 2001 Nov;134(5):977-84. doi: 10.1038/sj.bjp.0704329. urine protein amount male 210 days-224 days 0 37.0 mg/d 15.0 urine protein analysis 86400.0 0 metabolic cage; sulfosalicylic acid method 107474 3088
SHRSP/A3N ratio of deaths related to left ventricular hypertrophy to total study population during a period of time controlled sodium chloride content drinking water (1 %) (for 126 days) and controlled fat content diet (24.5 %) (for 126 days) and controlled carvedilol content diet (2400 ppm) (for 126 days) Barone FC, etal., Pharmacology. 2007;80(2-3):166-76. doi: 10.1159/000103384. Epub 2007 Jun 4. total life span male 203 days-224 days 20 0.0 % unspecified method 0.0 0 ratio of deaths related to left ventricular hypertrophy to total study population during a period of time (CMO:0003810) 107112 3075
SHRSP/A3N kidney total tubule cast count controlled sodium content drinking water (1 %) (for 126 days) and controlled fat content diet (24.5 %) (for 126 days) and controlled carvedilol content diet (2400 ppm) (for 126 days) Wong VY, etal., Br J Pharmacol. 2001 Nov;134(5):977-84. doi: 10.1038/sj.bjp.0704329. kidney integrity trait male 210 days-224 days 0 21.0 /section 11.0 ex vivo light microscopy with histochemistry 0.0 0 total tubular casts 107494 3088